Homocysteine and glutathione peroxidase-1

Antioxidants and Redox Signaling

Volumn 9, Issue 11, 2007, Pages 1923-1940

  Lubos, Edith ^a   Loscalzo, Joseph ^a,b   Handy, Diane E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CYANOCOBALAMIN; CYSTEINE; ENDOTHELIUM DERIVED RELAXING FACTOR; FOLIC ACID; GLUTATHIONE PEROXIDASE 1; HOMOCYSTEINE; METHIONINE; NITRIC OXIDE; PYRIDOXINE; REACTIVE OXYGEN METABOLITE; SELENOCYSTEINE;

AMINO ACID METABOLISM; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; ENDOTHELIAL DYSFUNCTION; GENETIC DISORDER; GENETIC VARIABILITY; HUMAN; HYPERHOMOCYSTEINEMIA; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THROMBOSIS; VASCULAR DISEASE;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL AVAILABILITY; ENDOTHELIUM, VASCULAR; EVIDENCE-BASED MEDICINE; GLUTATHIONE PEROXIDASE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; THROMBOSIS;

EID: 35449005350     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1771     Document Type: Review

References (233)

1. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288: 2015-2022, 2002.
2. Acevedo M, Pearce GL, Kottke-Marchant K, and Sprecher DL. Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic. Arterioscler Thromb Vasc Biol 22: 1042-1045, 2002.
3. Alfthan G, Aro A, and Gey KF. Plasma homocysteine and cardiovascular disease mortality. Lancet 349: 397, 1997.
4. Allain P, Le Bouil A, Cordillet E, Le Quay L, Bagheri H, and Montastruc JL. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 16: 527-529, 1995.
5. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, and Pearson RR. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 102: 1227-1232, 2000.
6. Ashfield-Watt PA, Moat SJ, Doshi SN, and McDowell IF. Folate, homocysteine, endothelial function and cardiovascular disease. What is the link? Biomed Pharmacother 55: 425-433, 2001.
7. Austin RC, Lentz SR, and Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 11 Suppl 1: S56-64, 2004.
8. Babior BM. NADPH oxidase: an update. Blood 93: 1464-1476, 1999.
9. Bagi Z, Cseko C, Toth E, and Koller A. Oxidative stress-induced dysregulation of arteriolar wall shear stress and blood pressure in hyperhomocysteinemia is prevented by chronic vitamin C treatment. Am J Physiol Heart Circ Physiol 285: H2277-2283, 2003.
10. Bagi Z, Ungvari Z, Szollar L, and Koller A. Flow-induced constriction in arterioles of hyperhomocysteinemic rats is due to impaired nitric oxide and enhanced thromboxane A(2) mediation. Arterioscler Thromb Vasc Biol 21: 233-237, 2001.
11. Basu TK and Mann S. Vitamin B-6 normalizes the altered sulfur amino acid status of rats fed diets containing pharmacological levels of niacin without reducing niacin's hypolipidemic effects. J Nutr 127: 117-121, 1997.
12. Baumbach GL, Sigmund CD, Bottiglieri T, and Lentz SR. Structure of cerebral arterioles in cystathionine beta-synthase-deficient mice. Circ Res 91: 931-937, 2002.
13. Bautista LE, Arenas IA, Penuela A, and Martinez LX. Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J Clin Epidemiol 55: 882-887, 2002.
14. Becker JS, Adler A, Schneeberger A, Huang H, Wang Z, Walsh E, Koller A, and Hintze TH. Hyperhomocysteinemia, a cardiac metabolic disease: role of nitric oxide and the p22phox subunit of NADPH oxidase. Circulation 111: 2112-2118, 2005.
15. Beckman JS, Beckman TW, Chen J, Marshall PA, and Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620-1624, 1990.
16. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Bones C, Newcombe RG, and Lewis MJ. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 98: 1848-1852, 1998.
17. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Newcombe RG, and Lewis MJ. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. Eur J Clin Invest 29: 659-662, 1999.
18. Berry MJ. Insights into the hierarchy of selenium incorporation. Nat Genet 37: 1162-1163, 2005.
19. Berry MJ, Harney JW, Ohama T, and Hatfield DL. Selenocysteine insertion or termination: factors affecting UGA codon fate and complementary anticodon:codon mutations. Nucleic Acids Res 22: 3753-3759, 1994.
20. Berry MJ, Tujebajeva RM, Copeland PR, Xu XM, Carlson BA, Martin GW, 3rd, Low SC, Mansell JB, Grundner-Culemann E, Harney JW, Driscoll DM, and Hatfield DL. Selenocysteine incorporation directed from the 3'UTR: characterization of eukaryotic EFsec and mechanistic implications. Biofactors 14: 17-24, 2001.
21. Bey EA, Xu B, Bhattacharjee A, Oldfield CM, Zhao X, Li Q, Subbulakshmi V, Feldman GM, Wientjes FB, and Cathcart MK. Protein kinase C delta is required for p47phox phosphorylation and translocation in activated human monocytes. J Immunol 173: 5730-5738, 2004.
22. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, Smieja M, Cambien F, Meyer J, and Lackner KJ. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 349: 1605-1613, 2003.
23. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, and Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 20: 1557-1564, 2000.
24. Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, and Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 100: 161-167, 2001.
25. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, and Rasmussen K. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354: 1578-1588, 2006.
26. Booth GL and Wang EE. Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care. Cmaj 163: 21-29, 2000.
27. Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, Jacques PF, and Wilson PW. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 159: 1077-1080, 1999.
28. Boushey CJ, Beresford SA, Omenn GS, and Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274: 1049-1057, 1995.
29. Brattstrom L, Wilcken DE, Ohrvik J, and Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 98: 2520-2526, 1998.
30. Cai H and Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87: 840-844, 2000.
31. Cathcart MK. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler Thromb Vasc Biol 24: 23-28, 2004.
32. Chambers JC, McGregor A, Jean-Marie J, and Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 351: 36-37, 1998.
33. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, and Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation 99: 1156-1160, 1999.
34. Chambers JC, Obeid OA, and Kooner JS. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb Vasc Biol 19: 2922-2927, 1999.
35. Chao CL, Kuo TL, and Lee YT. Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. Circulation 101: 485-490, 2000.
36. Chao CL, Tsai HH, Lee CM, Hsu SM, Kao JT, Chien KL, Sung FC, and Lee YT. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis 147: 379-386, 1999.
37. Chasan-Taber L, Selhub J, Rosenberg IH, Malinow MR, Terry P, Tishler PV, Willett W, Hennekens CH, and Stampfer MJ. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 15: 136-143, 1996.
38. Cheng SW, Ting AC, and Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg 11: 217-223, 1997.
39. Chern CL, Huang RF, Chen YH, Cheng JT, and Liu TZ. Folate deficiency-induced oxidative stress and apoptosis are mediated via homocysteine-dependent overproduction of hydrogen peroxide and enhanced activation of NF-kappaB in human Hep G2 cells. Biomed Pharmacother 55: 434-442, 2001.
40. Christen WG and Ridker PM. Blood levels of homocysteine and atherosclerotic vascular disease. Curr Atheroscler Rep 2: 194-199, 2000.
41. Clarke R and Armitage J. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Semin Thromb Hemost 26: 341-348, 2000.
42. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, and Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324: 1149-1155, 1991.
43. Cohen HJ, Chovaniec ME, Mistretta D, and Baker SS. Selenium repletion and glutathione peroxidase-differential effects on plasma and red blood cell enzyme activity. Am J Clin Nutr 41: 735-747, 1985.
44. Cox DG, Hankinson SE, Kraft P, and Hunter DJ. No association between GPX1 Pro198Leu and breast cancer risk. Cancer Epidemiol Biomarkers Prev 13: 1821-1822, 2004.
45. Dayal S, Arning E, Bottiglieri T, Boger RH, Sigmund CD, Faraci FM, and Lentz SR. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Stroke 35: 1957-1962, 2004.
46. Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR, Sigmund CD, Heistad DD, Faraci FM, and Lentz SR. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. Circ Res 88: 1203-1209, 2001.
47. Dayal S, Brown KL, Weydert CJ, Oberley LW, Arning E, Bottiglieri T, Faraci FM, and Lentz SR. Deficiency of glutathione peroxidase-1 sensitizes hyperhomocysteinemic mice to endothelial dysfunction. Arterioscler Thromb Vasc Biol 22: 1996-2002, 2002.
48. de Haan JB, Bladier C, Griffiths P, Kelner M, O'Shea RD, Cheung NS, Bronson RT, Silvestro MJ, Wild S, Zheng SS, Beart PM, Hertzog PJ, and Kola I. Mice with a homozygous null mutation for the most abundant glutathione peroxidase, Gpx1, show increased susceptibility to the oxidative stress-inducing agents paraquat and hydrogen peroxide. J Biol Chem 273: 22528-22536, 1998.
49. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, and Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334: 759-762, 1996.
50. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, and Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 80: 874-877, 1998.
51. Devlin AM, Arning E, Bottiglieri T, Faraci FM, Rozen R, and Lentz SR. Effect of Mthfr genotype on diet-induced hyperhomocysteinemia and vascular function in mice. Blood 103: 2624-2629, 2004.
52. Doshi SN, McDowell IF, Moat SJ, Payne N, Durrant HJ, Lewis MJ, and Goodfellow J. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 105: 22-26, 2002.
53. Driscoll DM and Copeland PR. Mechanism and regulation of selenoprotein synthesis. Annu Rev Nutr 23: 17-40, 2003.
54. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Stark R, Klings ES, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, and Loscalzo J. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 106: 483-491, 2000.
55. Eikelboom JW, Lonn E, Genest J, Jr., Hankey G, and Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 131: 363-375, 1999.
56. Espinola-Klein C, Rupprecht HJ, Bickel C, Schnabel R, Genth-Zotz S, Torzewski M, Lackner K, Munzel T, and Blankenberg S. Glutathione peroxidase-1 activity, atherosclerotic burden, and cardiovascular prognosis. Am J Cardiol 99: 808-812, 2007.
57. Faraci FM. Hyperhomocysteinemia: a million ways to lose control. Arterioscler Thromb Vasc Biol 23: 371-373, 2003.
58. Finkelstein JD, Kyle W, and Harris BJ. Methionine metabolism in mammals. Regulation of homocysteine methyltransferases in rat tissue. Arch Biochem Biophys 146: 84-92, 1971.
59. Flohe L. Glutathione peroxidase. Basic Life Sci 49: 663-668, 1988.
60. Forgione MA, Cap A, Liao R, Moldovan NI, Eberhardt RT, Lim CC, Jones J, GoldschmidtpClermont PJ, and Loscalzo J. Heterozygous cellular glutathione peroxidase deficiency in the mouse: abnormalities in vascular and cardiac function and structure. Circulation 106: 1154-1158, 2002.
61. Forgione MA, Weiss N, Heydrick S, Cap A, Klings ES, Bierl C, Eberhardt RT, Farber HW, and Loscalzo J. Cellular glutathione peroxidase deficiency and endothelial dysfunction. Am J Physiol Heart Circ Physiol 282: H1255-1261, 2002.
62. Forsberg L, de Faire U, and Morgenstern R. Low yield of polymorphisms from EST blast searching: analysis of genes related to oxidative stress and verification of the P197L polymorphism in GPX1. Hum Mutat 13: 294-300, 1999.
63. Freedman JE, Frei B, Welch GN, and Loscalzo J. Glutathione peroxidase potentiates the inhibition of platelet function by S-nitrosothiols. J Clin Invest 96: 394-400, 1995.
64. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, and et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111-113, 1995.
65. Galasso G, Schiekofer S, Sato K, Shibata R, Handy DE, Ouchi N, Leopold JA, Loscalzo J, and Walsh K. Impaired angiogenesis in glutathione peroxidase-1-deficient mice is associated with endothelial progenitor cell dysfunction. Circ Res 98: 254-261, 2006.
66. Gellink H, den Heijer M, Heil SG, and Blom HJ. Genetic determinants of plasma total homocysteine. Semin Vasc Med 5: 98-109, 2005.
67. Ghigo D, Alessio P, Foco A, Bussolino F, Costamagna C, Heller R, Garbarino G, Pescarmona GP, and Bosia A. Nitric oxide synthesis is impaired in glutathione-depleted human umbilical vein endothelial cells. Am J Physiol 265: C728-732, 1993.
68. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277: 1775-1781, 1997.
69. Griendling KK, Sorescu D, and Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86: 494-501, 2000.
70. Gryglewski RJ, Palmer RM, and Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320: 454-456, 1986.
71. Guttormsen AB, Mansoor AM, Fiskerstrand T, Ueland PM, and Refsum H. Kinetics of plasma homocysteine in healthy subjects after peroral homocysteine loading. Clin Chem 39: 1390-1397, 1993.
72. Haddad IY, Pataki G, Hu P, Galliani C, Beckman JS, and Matalon S. Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury. J Clin Invest 94: 2407-2413, 1994.
73. Hamanishi T, Furuta H, Kato H, Doi A, Tamai M, Shimomura H, Sakagashira S, Nishi M, Sasaki H, Sanke T, and Nanjo K. Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in japanese type 2 diabetic patients. Diabetes 53: 2455-2460, 2004.
74. Handy DE, Hang G, Scolaro J, Metes N, Razaq N, Yang Y, and Loscalzo J. Aminoglycosides decrease glutathione peroxidase-1 activity by interfering with selenocysteine incorporation. J Biol Chem 281: 3382-3388, 2006.
75. Handy DE, Zhang Y, and Loscalzo J. Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J Biol Chem 280: 15518-15525, 2005.
76. Hanratty CG, McAuley DF, McGurk C, Young IS, and Johnston GD. Homocysteine and endothelial vascular function. Lancet 351: 1288-1289, 1998.
77. Heinecke JW, Rosen H, Suzuki LA, and Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 262: 10098-10103, 1987.
78. Heydrick SJ, Weiss N, Thomas SR, Cap AP, Pimentel DR, Loscalzo J, and Keaney JF, Jr. L-Homocysteine and L-homocystine stereospecifically induce endothelial nitric oxide synthase-dependent lipid peroxidation in endothelial cells. Free Radic Biol Med 36: 632-640, 2004.
79. Hirano K, Ogihara T, Miki M, Yasuda H, Tamai H, Kawamura N, and Mino M. Homocysteine induces iron-catalyzed lipid peroxidation of low-density lipoprotein that is prevented by alpha-tocopherol. Free Radic Res 21: 267-276, 1994.
80. Holven KB, Holm T, Aukrust P, Christensen B, Kjekshus J, Andreassen AK, Gullestad L, Hagve TA, Svilaas A, Ose L, and Nenseter MS. Effect of folic acid treatment on endothelium-dependent vasodilation and nitric oxide-derived end products in hyperhomocysteinemic subjects. Am J Med 110: 536-542, 2001.
81. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, and Stehouwer CD. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study. Circulation 101: 1506-1511, 2000.
82. Hu YJ and Diamond AM. Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. Cancer Res 63: 3347-3351, 2003.
83. Huang RF, Hsu YC, Lin HL, and Yang FL. Folate depletion and elevated plasma homocysteine promote oxidative stress in rat livers. J Nutr 131: 33-38, 2001.
84. Ichimura Y, Habuchi T, Tsuchiya N, Wang L, Oyama C, Sato K, Nishiyama H, Ogawa O, and Kato T. Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. J Urol 172: 728-732, 2004.
85. Ishida K, Morino T, Takagi K, and Sukenaga Y. Nucleotide sequence of a human gene for glutathione peroxidase. Nucleic Acids Res 15: 10051, 1987.
86. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, and Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99: 3092-3095, 1999.
87. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M, Ji J, Otto JM, and Taylor LM, Jr. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 40: 873-881, 1994.
88. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, and Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93: 7-9, 1996.
89. Jiang X, Yang F, Tan H, Liao D, Bryan RM Jr, Randhawa JK, Rumbaut RE, Durante W, Schafer AI, Yang X, and Wang H. Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol 25: 2515-2521, 2005.
90. Johannsmann R, Hellkuhl B, and Grzeschik KH. Regional mapping of human chromosome 3. Assignment of a glutathione peroxidase-1 gene to 3p13 leads to 3q12. Hum Genet 56: 361-363, 1981.
91. Jones BG, Rose FA, and Tudball N. Lipid peroxidation and homocysteine induced toxicity. Atherosclerosis 105: 165-170, 1994.
92. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, and Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 100: 1161-1168, 1999.
93. Kang SS, Wong PW, and Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 12: 279-298, 1992.
94. Kang SS, Zhou J, Wong PW, Kowalisyn J, and Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 43: 414-421, 1988.
95. Kiss C, Li J, Szeles A, Gizatullin RZ, Kashuba VI, Lushnikova T, Protopopov AI, Kelve M, Kiss H, Kholodnyuk ID, Imreh S, Klein G, and Zabarovsky ER. Assignment of the ARHA and GPX1 genes to human chromosome bands 3p21.3 by in situ hybridization and with somatic cell hybrids. Cytogenet Cell Genet 79: 228-230, 1997.
96. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, and Schouten EG. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 288: 2023-2031, 2002.
97. Kluijtmans LA, Kastelein JJ, Lindemans J, Boers GH, Heil SG, Bruschke AV, Jukema JW, van den Heuvel LP, Trijbels FJ, Boerma GJ, Verheugt FW, Willems F, and Blom HJ. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation 96: 2573-2577, 1997.
98. Knekt P, Alfthan G, Aromaa A, Heliovaara M, Marniemi J, Rissanen H, and Reunanen A. Homocysteine and major coronary events: a prospective population study amongst women. J Intern Med 249: 461-465, 2001.
99. Knekt P, Reunanen A, Alfthan G, Heliovaara M, Rissanen H, Marniemi J, and Aromaa A. Hyperhomocystinemia: a risk factor or a consequence of coronary heart disease? Arch Intern Med 161: 1589-1594, 2001.
100. Knight JA, Onay UV, Wells S, Li H, Shi EJ, Andrulis IL, and Ozcelik H. Genetic variants of GPX1 and SOD2 and breast cancer risk at the Ontario site of the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 13: 146-149, 2004.
101. Kraus JP, Janosik M, Kozich V, Mandell R, Shih V, Sperandeo MP, Sebastio G, de Franchis R, Andria G, Kluijtmans LA, Blom H, Boers GH, Gordon RB, Kamoun P, Tsai MY, Kruger WD, Koch HG, Ohura T, and Gaustadnes M. Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat 13: 362-375, 1999.
102. Lackner KJ and Blankenberg S. Atherosclerosis, oxidative stress and glutathione peroxidase-1: a new kid on the block. Ital Heart J 5: 169-172, 2004.
103. Lang D, Kredan MB, Moat SJ, Hussain SA, Powell CA, Bellamy MF, Powers HJ, and Lewis MJ. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions. Arterioscler Thromb Vasc Biol 20: 422-427, 2000.
104. Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, and Dambrink JH. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350: 2673-2681, 2004.
105. Lapenna D, de Gioia S, Ciofani G, Mezzetti A, Ucchino S, Calafiore AM, Napolitano AM, Di Ilio C, and Cuccurullo F. Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation 97: 1930-1934, 1998.
106. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, Tarpey M, Fukai T, and Harrison DG. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 103: 1282-1288, 2001.
107. Lawrence de Koning AB, Werstuck GH, Zhou J, and Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 36: 431-441, 2003.
108. Lentz SR. Does homocysteine promote atherosclerosis? Arterioscler Thromb Vasc Biol 21: 1385-1386, 2001.
109. Lentz SR, Erger RA, Dayal S, Maeda N, Malinow MR, Heistad DD, and Faraci FM. Folate dependence of hyperhomocysteinemia and vascular dysfunction in cystathionine beta-synthase-deficient mice. Am J Physiol Heart Circ Physiol 279: H970-975, 2000.
110. Lentz SR and Haynes WG. Homocysteine: is it a clinically important cardiovascular risk factor? Cleve Clin J Med 71: 729-734, 2004.
111. Lentz SR, Malinow MR, Piegors DJ, Bhopatkar-Teredesai M, Faraci FM, and Heistad DD. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. Arterioscler Thromb Vasc Biol 17: 2930-2934, 1997.
112. Lentz SR and Sadler JE. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 81: 683-689, 1993.
113. Lentz SR and Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88: 1906-1914, 1991.
114. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, and Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 98: 24-29, 1996.
115. Leonard JL, Leonard DM, Shen Q, Farwell AP, and Newburger PE. Selenium-regulated translation control of heterologous gene expression: normal function of selenocysteine-substituted gene products. J Cell Biochem 61: 410-419, 1996.
116. Leoncini G, Pascale R, and Signorello MG. Effects of homocysteine on L-arginine transport and nitric oxide formation in human platelets. Eur J Clin Invest 33: 713-719, 2003.
117. Lescure A, Fagegaltier D, Carbon P, and Krol A. Protein factors mediating selenoprotein synthesis. Curr Protein Pept Sci 3: 143-151, 2002.
118. Lesoon A, Mehta A, Singh R, Chisolm GM, and Driscoll DM. An RNA-binding protein recognizes a mammalian selenocysteine insertion sequence element required for cotranslational incorporation of selenocysteine. Mol Cell Biol 17: 1977-1985, 1997.
119. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, and Genest J, Jr. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354: 1567-1577, 2006.
120. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 98: 5-7, 1996.
121. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, and Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315: 1046-1051, 1986.
122. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC, and Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 94: 2410-2416, 1996.
123. Malinow MR, Bostom AG, and Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 99: 178-182, 1999.
124. Malinow MR, Nieto FJ, Szklo M, Chambless LE, and Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 87: 1107-1113, 1993.
125. Mansoor MA, Bergmark C, Svardal AM, Lonning PE, and Ueland PM. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Homocysteine and peripheral vascular disease. Arterioscler Thromb Vasc Biol 15: 232-240, 1995.
126. Mansoor MA, Guttormsen AB, Fiskerstrand T, Refsum H, Ueland PM, and Svardal AM. Redox status and protein binding of plasma aminothiols during the transient hyperhomocysteinemia that follows homocysteine administration. Clin Chem 39: 980-985, 1993.
127. Mansoor MA, Svardal AM, Schneede J, and Ueland PM. Dynamic relation between reduced, oxidized, and protein-bound homocysteine and other thiol components in plasma during methionine loading in healthy men. Clin Chem 38: 1316-1321, 1992.
128. Mansoor MA, Ueland PM, Aarsland A, and Svardal AM. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with homocystinuria. Metabolism 42: 1481-1485, 1993.
129. Mansoor MA, Ueland PM, and Svardal AM. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with hyperhomocysteinemia due to cobalamin deficiency. Am J Clin Nutr 59: 631-635, 1994.
130. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56: 111-128, 1969.
131. McDermott JR. Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem J 154: 179-184, 1976.
132. McLenachan JM, Williams JK, Fish RD, Ganz P, and Selwyn AP. Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation 84: 1273-1278, 1991.
133. Moscow JA, Schmidt L, Ingram DT, Gnarra J, Johnson B, and Cowan KH. Loss of heterozygosity of the human cytosolic glutathione peroxidase I gene in lung cancer. Carcinogenesis 15: 2769-2773, 1994.
134. Mudd SH, Finkelstein JD, Irreverre F, and Laster L. Transsulfuration in mammals. Microassays and tissue distributions of three enzymes of the pathway. J Biol Chem 240: 4382-4392, 1965.
135. Mudd SH, Finkelstein JD, Refsum H, Ueland PM, Malinow MR, Lentz SR, Jacobsen DW, Brattstrom L, Wilcken B, Wilcken DE, Blom HJ, Stabler SP, Allen RH, Selhub J, and Rosenberg IH. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol 20: 1704-1706, 2000.
136. Mujumdar VS, Aru GM, and Tyagi SC. Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biochem 82: 491-500, 2001.
137. Murray CJ and Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349: 1436-1442, 1997.
138. Napoli C and Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide 5: 88-97, 2001.
139. Nappo F, De Rosa N, Marfella R, De Lucia D, Ingrosso D, Perna AF, Farzati B, and Giugliano D. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 281: 2113-2118, 1999.
140. Nishio E and Watanabe Y. Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for hydrogen peroxide. Br J Pharmacol 122: 269-274, 1997.
141. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, and Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337: 230-236, 1997.
142. O'Donnell VB and Freeman BA. Interactions between nitric oxide and lipid oxidation pathways: implications for vascular disease. Circ Res 88: 12-21, 2001.
143. Omland T, Samuelsson A, Hartford M, Herlitz J, Karlsson T, Christensen B, and Caidahl K. Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes. Arch Intern Med 160: 1834-1840, 2000.
144. Outinen PA, Sood SK, Liaw PC, Sarge KD, Maeda N, Hirsh J, Ribau J, Podor TJ, Weitz JI, and Austin RC. Characterization of the stress-inducing effects of homocysteine. Biochem J 332 (Pt 1): 213-221, 1998.
145. Outinen PA, Sood SK, Pfeifer SI, Pamidi S, Podor TJ, Li J, Weitz JI, and Austin RC. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood 94: 959-967, 1999.
146. Paglia DE and Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70: 158-169, 1967.
147. Parnetti L, Caso V, Santucci A, Corea F, Lanari A, Floridi A, Conte C, and Bottiglieri T. Mild hyperhomocysteinemia is a risk-factor in all etiological subtypes of stroke. Neurol Sci 25: 13-17, 2004.
148. Perona G, Guidi GC, Piga A, Cellerino R, Milani G, Colautti P, Moschini G, and Stievano BM. Neonatal erythrocyte glutathione peroxidase deficiency as a consequence of selenium imbalance during pregnancy. Br J Haematol 42: 567-574, 1979.
149. Persa C, Pierce A, Ma Z, Kabil O, and Lou MF. The presence of a transsulfuration pathway in the lens: a new oxidative stress defense system. Exp Eye Res 79: 875-886, 2004.
150. Pirro M, Schillaci G, Mannarino MR, Savarese G, Vaudo G, Siepi D, Paltriccia R, and Mannarino E. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. Nutr Metab Cardiovasc Dis, 2006.
151. Pritchard KA, Jr., Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, Wolin MS, and Stemerman MB. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 77: 510-518, 1995.
152. Quere I, Hillaire-Buys D, Brunschwig C, Chapal J, Janbon C, Blayac JP, Petit P, and Loubatieres-Mariani MM. Effects of homocysteine on acetylcholine- and adenosine-induced vasodilatation of pancreatic vascular bed in rats. Br J Pharmacol 122: 351-357, 1997.
153. Raghuveer G, Sinkey CA, Chenard C, Stumbo P, and Haynes WG. Effect of vitamin E on resistance vessel endothelial dysfunction induced by methionine. Am J Cardiol 88: 285-290, 2001.
154. Ratnasinghe D, Tangrea JA, Andersen MR, Barrett MJ, Virtamo J, Taylor PR, and Albanes D. Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res 60: 6381-6383, 2000.
155. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, and Lee AS. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 278: 20915-20924, 2003.
156. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, and Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 281: 1817-1821, 1999.
157. Riedijk MA, Stoll B, Chacko S, Schierbeek H, Sunehag AL, van Goudoever JB, and Burrin DG. Methionine transmethylation and transsulfuration in the piglet gastrointestinal tract. Proc Natl Acad Sci USA 104: 3408-3413, 2007.
158. Robinson K. Homocysteine, B vitamins, and risk of cardiovascular disease. Heart 83: 127-130, 2000.
159. Rogers JD, Sanchez-Saffon A, Frol AB, and Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 60: 59-64, 2003.
160. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126, 1999.
161. Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B, Barnes S, Kirk M, and Freeman BA. Nitric oxide regulation of superoxide and peroxynitrite- dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem 269: 26066-26075, 1994.
162. Rutkowski DT and Kaufman RJ. A trip to the ER: coping with stress. Trends Cell Biol 14: 20-28, 2004.
163. Schachinger V, Britten MB, and Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101: 1899-1906, 2000.
164. Schnabel R, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Torzewski M, Lubos E, Bickel C, Cambien F, Tiret L, Munzel T, and Blankenberg S. Glutathione peroxidase-1 and homocysteine for cardiovascular risk prediction: results from the AtheroGene study. J Am Coll Cardiol 45: 1631-1637, 2005.
165. Schneede J, Refsum H, and Ueland PM. Biological and environmental determinants of plasma homocysteine. Semin Thromb Hemost 26: 263-279, 2000.
166. Schnyder G, Pin R, Roffi M, Flammer Y, and Hess OM. Association of plasma homocysteine with the number of major coronary arteries severely narrowed. Am J Cardiol 88: 1027-1030, 2001.
167. Selhub J. Homocysteine metabolism. Annu Rev Nutr 19: 217-246, 1999.
168. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, and Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 332: 286-291, 1995.
169. Selhub J, Jacques PF, Wilson PW, Rush D, and Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270: 2693-2698, 1993.
170. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, and Jacobsen DW. Relative roles of albumin and ceruloplasmin in the formation of homocystine, homocysteine-cysteine-mixed disulfide, and cystine in circulation. J Biol Chem 276: 46896-46904, 2001.
171. Shen Q, Leonard JL, and Newburger PE. Structure and function of the selenium translation element in the 3′-untranslated region of human cellular glutathione peroxidase mRNA. RNA 1: 519-525, 1995.
172. Shen Q, Townes PL, Padden C, and Newburger PE. An in-frame trinucleotide repeat in the coding region of the human cellular glutathione peroxidase (GPX1) gene: in vivo polymorphism and in vitro instability. Genomics 23: 292-294, 1994.
173. Shiomi T, Tsutsui H, Matsusaka H, Murakami K, Hayashidani S, Ikeuchi M, Wen J, Kubota T, Utsumi H, and Takeshita A. Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 109: 544-549, 2004.
174. Sies H, Sharov VS, Klotz LO, and Briviba K. Glutathione peroxidase protects against peroxynitrite-mediated oxidations. A new function for selenoproteins as peroxynitrite reductase. J Biol Chem 272: 27812-27817, 1997.
175. Siow YL, Au-Yeung KK, Woo CW, and O K. Homocysteine stimulates phosphorylation of NADPH oxidase p47phox and p67phox subunits in monocytes via protein kinase Cbeta activation. Biochem J 398: 73-82, 2006.
176. Sparrow CP and Olszewski J. Cellular oxidation of low density lipoprotein is caused by thiol production in media containing transition metal ions. J Lipid Res 34: 1219-1228, 1993.
177. Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, and Pryor WA. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 376: 333-337, 2000.
178. Stadtman TC. Selenocysteine. Annu Rev Biochem 65: 83-100, 1996.
179. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, and Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268: 877-881, 1992.
180. Starkebaum G and Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 77: 1370-1376, 1986.
181. Stead LM, Au KP, Jacobs RL, Brosnan ME, and Brosnan JT. Methylation demand and homocysteine metabolism: effects of dietary provision of creatine and guanidinoacetate. Am J Physiol Endocrinol Metab 281: E1095-1100, 2001.
182. Stehouwer CD, Gall MA, Hougaard P, Jakobs C, and Parving HH. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int 55: 308-314, 1999.
183. Streifler JY, Rosenberg N, Chetrit A, Eskaraev R, Sela BA, Dardik R, Zivelin A, Ravid B, Davidson J, Seligsohn U, and Inbal A. Cerebrovascular events in patients with significant stenosis of the carotid artery are associated with hyperhomocysteinemia and platelet antigen-1 (Leu33Pro) polymorphism. Stroke 32: 2753-2758, 2001.
184. Stubbs PJ, Al-Obaidi MK, Conroy RM, Collinson PO, Graham IM, and Noble IM. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation 102: 605-610, 2000.
185. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, Szuba A, Malinow MR, Wascher TC, Pachinger O, and Cooke JP. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 108: 933-938, 2003.
186. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, and Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104: 2569-2575, 2001.
187. Suematsu N, Ojaimi C, Kinugawa S, Wang Z, Xu X, Koller A, Recchia FA, and Hintze TH. Hyperhomocysteinemia alters cardiac substrate metabolism by impairing nitric oxide bioavailability through oxidative stress. Circulation 115: 255-262, 2007.
188. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Jr., and Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101: 948-954, 2000.
189. Takahashi K, Newburger PE, and Cohen HJ. Glutathione peroxidase protein. Absence in selenium deficiency states and correlation with enzymatic activity. J Clin Invest 77: 1402-1404, 1986.
190. Tawakol A, Omland T, Gerhard M, Wu JT, and Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 95: 1119-1121, 1997.
191. Taylor LM, Jr., Moneta GL, Sexton GJ, Schuff RA, and Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 29: 8-19; discussion 19-21, 1999.
192. Ter Horst GJ, Knollema S, Stuiver B, Hom H, Yoshimura S, Ruiters MH, and Korf J. Differential glutathione peroxidase mRNA up-regulations in rat forebrain areas after transient hypoxia-ischemia. Ann NY Acad Sci 738: 329-333, 1994.
193. Title LM, Cummings PM, Giddens K, Genest JJ Jr, and Nassar BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 36: 758-765, 2000.
194. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, and Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291: 565-575, 2004.
195. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, and Lee ME. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 91: 6369-6373, 1994.
196. Ueland PM, Refsum H, Beresford SA, and Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72: 324-332, 2000.
197. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, and Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 39: 1764-1779, 1993.
198. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G, and Koller A. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 23: 418-424, 2003.
199. Ungvari Z, Pacher P, Rischak K, Szollar L, and Koller A. Dysfunction of nitric oxide mediation in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 19: 1899-1904, 1999.
200. Upchurch GR, Jr., Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, and Loscalzo J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 272: 17012-17017, 1997.
201. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, and Imaizumi T. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid. Clin Sci (Lond) 96: 235-239, 1999.
202. Vallance P, Leone A, Calver A, Collier J, and Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 20 Suppl 12: S60-62, 1992.
203. van den Berg M, Stehouwer CD, Bierdrager E, and Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 16: 165-171, 1996.
204. Van Heerebeek L, Meischl C, Stooker W, Meijer CJ, Niessen HW, and Roos D. NADPH oxidase(s): new source(s) of reactive oxygen species in the vascular system? J Clin Pathol 55: 561-568, 2002.
205. Verhoef P, Kok FJ, Kruyssen DA, Schouten EG, Witteman JC, Grobbee DE, Ueland PM, and Refsum H. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 17: 989-995, 1997.
206. Virdis A, Iglarz M, Neves MF, Amiri F, Touyz RM, Rozen R, and Schiffrin EL. Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice. Arterioscler Thromb Vasc Biol 23: 1352-1357, 2003.
207. von Bohlen und Halbach O. Nitric oxide imaging in living neuronal tissues using fluorescent probes. Nitric Oxide 9: 217-228, 2003.
208. von Eckardstein A, Malinow MR, Upson B, Heinrich J, Schulte H, Schonfeld R, Kohler E, and Assmann G. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb 14: 460-464, 1994.
209. Wald DS, Law M, and Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325: 1202, 2002.
210. Wall RT, Harlan JM, Harker LA, and Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 18: 113-121, 1980.
211. Weisbrot-Lefkowitz M, Reuhl K, Perry B, Chan PH, Inouye M, and Mirochnitchenko O. Overexpression of human glutathione peroxidase protects transgenic mice against focal cerebral ischemia/reperfusion damage. Brain Res Mol Brain Res 53: 333-338, 1998.
212. Weiss N, Heydrick S, Zhang YY, Bierl C, Cap A, and Loscalzo J. Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase-deficient mice. Arterioscler Thromb Vasc Biol 22: 34-41, 2002.
213. Weiss N, Heydrick SJ, Postea O, Keller C, Keaney JF Jr, and Loscalzo J. Influence of hyperhomocysteinemia on the cellular redox state - impact on homocysteine-induced endothelial dysfunction. Clin Chem Lab Med 41: 1455-1461, 2003.
214. Weiss N, Keller C, Hoffmann U, and Loscalzo J. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 7: 227-239, 2002.
215. Weiss N, Zhang YY, Heydrick S, Bierl C, and Loscalzo J. Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction. Proc Natl Acad Sci U S A 98: 12503-12508, 2001.
216. Werstuck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, Shi YY, Zhou J, Maeda N, Krisans SK, Malinow MR, and Austin RC. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 107: 1263-1273, 2001.
217. Westphal S, Dierkes J, and Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 358: 39-40, 2001.
218. Whincup PH, Refsum H, Perry IJ, Morris R, Walker M, Lennon L, Thomson A, Ueland PM, and Ebrahim SB. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart 82: 448-454, 1999.
219. Wijnen LM, Monteba-van Heuvel M, Pearson PL, and Meera Khan P. Assignment of a gene for glutathione peroxidase (GPX1) to human chromosome 3. Cytogenet Cell Genet 22: 232-235, 1978.
220. Wilcken DE and Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 20: 295-300, 1997.
221. Wilcken DE and Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 57: 1079-1082, 1976.
222. Willinek WA, Ludwig M, Lennarz M, Holler T, and Stumpe KO. High-normal serum homocysteine concentrations are associated with an increased risk of early atherosclerotic carotid artery wall lesions in healthy subjects. J Hypertens 18: 425-430, 2000.
223. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, and Celermajer DS. Hyperhomocyst( e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 96: 2542-2544, 1997.
224. Wood JL and Graham A. Structural requirements for oxidation of low-density lipoprotein by thiols. FEBS Lett 366: 75-80, 1995.
225. Yoshida T, Watanabe M, Engelman DT, Engelman RM, Schley JA, Maulik N, Ho YS, Oberley TD, and Das DK. Transgenic mice overexpressing glutathione peroxidase are resistant to myocardial ischemia reperfusion injury. J Mol Cell Cardiol 28: 1759-1767, 1996.
226. Zai A, Rudd MA, Scribner AW, and Loscalzo J. Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. J Clin Invest 103: 393-399, 1999.
227. Zaina S, Lindholm MW, and Lund G. Nutrition and aberrant DNA methylation patterns in atherosclerosis: more than just hyperhomocysteinemia? J Nutr 135: 5-8, 2005.
228. Zavacki AM, Mansell JB, Chung M, Klimovitsky B, Harney JW, and Berry MJ. Coupled tRNA(Sec)-dependent assembly of the selenocysteine decoding apparatus. Mol Cell 11: 773-781, 2003.
229. Zhang C, Cai Y, Adachi MT, Oshiro S, Aso T, Kaufman RJ, and Kitajima S. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem 276: 35867-35874, 2001.
230. Zhang F, Slungaard A, Vercellotti GM, and Iadecola C. Superoxide-dependent cerebrovascular effects of homocysteine. Am J Physiol 274: R1704-1711, 1998.
231. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, and Goligorsky MS. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 279: F671-678, 2000.
232. Zhang Y, Handy DE, and Loscalzo J. Adenosine-dependent induction of glutathione peroxidase 1 in human primary endothelial cells and protection against oxidative stress. Circ Res 96: 831-837, 2005.
233. Zhou J, Werstuck GH, Lhotak S, de Koning AB, Sood SK, Hossain GS, Moller J, Ritskes-Hoitinga M, Falk E, Dayal S, Lentz SR, and Austin RC. Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice. Circulation 110: 207-213, 2004.